VERACYTE INC (VCYT) Stock Fundamental Analysis
NASDAQ:VCYT - Nasdaq - US92337F1075 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to VCYT. VCYT was compared to 572 industry peers in the Biotechnology industry. VCYT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VCYT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VCYT has reported negative net income.
VCYT had a positive operating cash flow in the past year.
VCYT had negative earnings in each of the past 5 years.
In multiple years VCYT reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of -0.73%, VCYT belongs to the best of the industry, outperforming 92.04% of the companies in the same industry.
The Return On Equity of VCYT (-0.79%) is better than 93.10% of its industry peers.
With an excellent Return On Invested Capital value of 0.60%, VCYT belongs to the best of the industry, outperforming 93.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.79% | ||
| ROIC | 0.6% |
ROA(3y)-5.4%
ROA(5y)-5.68%
ROE(3y)-5.81%
ROE(5y)-6.19%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT has a better Operating Margin (2.14%) than 93.63% of its industry peers.
VCYT has a Gross Margin of 68.45%. This is amongst the best in the industry. VCYT outperforms 82.12% of its industry peers.
VCYT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.14% | ||
| PM (TTM) | N/A | ||
| GM | 68.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y1.43%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VCYT is destroying value.
The number of shares outstanding for VCYT has been increased compared to 1 year ago.
Compared to 5 years ago, VCYT has more shares outstanding
VCYT has a better debt/assets ratio than last year.
2.2 Solvency
VCYT has an Altman-Z score of 21.81. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 21.81, VCYT belongs to the top of the industry, outperforming 92.74% of the companies in the same industry.
The Debt to FCF ratio of VCYT is 0.00, which is an excellent value as it means it would take VCYT, only 0.00 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.00, VCYT belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
VCYT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
VCYT has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 21.81 |
ROIC/WACC0.06
WACC10.75%
2.3 Liquidity
VCYT has a Current Ratio of 5.08. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT's Current ratio of 5.08 is in line compared to the rest of the industry. VCYT outperforms 54.34% of its industry peers.
VCYT has a Quick Ratio of 4.79. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.79, VCYT perfoms like the industry average, outperforming 53.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.79 |
3. Growth
3.1 Past
VCYT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.26%, which is quite impressive.
VCYT shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.95%.
Measured over the past years, VCYT shows a very strong growth in Revenue. The Revenue has been growing by 31.45% on average per year.
EPS 1Y (TTM)78.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.34%
Revenue 1Y (TTM)23.95%
Revenue growth 3Y45.38%
Revenue growth 5Y31.45%
Sales Q2Q%28.58%
3.2 Future
The Earnings Per Share is expected to grow by 29.09% on average over the next years. This is a very strong growth
Based on estimates for the next years, VCYT will show a quite strong growth in Revenue. The Revenue will grow by 11.87% on average per year.
EPS Next Y133.81%
EPS Next 2Y58.82%
EPS Next 3Y41.29%
EPS Next 5Y29.09%
Revenue Next Year24.95%
Revenue Next 2Y17.23%
Revenue Next 3Y14.98%
Revenue Next 5Y11.87%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
VCYT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 84.53 indicates a quite expensive valuation of VCYT.
Based on the Price/Forward Earnings ratio, VCYT is valued cheaper than 91.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.56, VCYT is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 84.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VCYT is valued cheaper than 93.45% of the companies in the same industry.
VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 93.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.41 | ||
| EV/EBITDA | 101.11 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VCYT's earnings are expected to grow with 41.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.82%
EPS Next 3Y41.29%
5. Dividend
5.1 Amount
No dividends for VCYT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERACYTE INC
NASDAQ:VCYT (1/31/2025, 8:00:01 PM)
After market: 46.5 +1.02 (+2.24%)45.48
-0.66 (-1.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.12%
Inst Owner Change0.28%
Ins Owners0.64%
Ins Owner Change-1.95%
Market Cap3.52B
Analysts82.22
Price Target45.39 (-0.2%)
Short Float %3.63%
Short Ratio3.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)550.71%
Min EPS beat(2)522.32%
Max EPS beat(2)579.09%
EPS beat(4)3
Avg EPS beat(4)219.85%
Min EPS beat(4)-309.68%
Max EPS beat(4)579.09%
EPS beat(8)6
Avg EPS beat(8)101.91%
EPS beat(12)10
Avg EPS beat(12)77.99%
EPS beat(16)12
Avg EPS beat(16)59.31%
Revenue beat(2)2
Avg Revenue beat(2)7.66%
Min Revenue beat(2)3.44%
Max Revenue beat(2)11.88%
Revenue beat(4)4
Avg Revenue beat(4)5.42%
Min Revenue beat(4)1.69%
Max Revenue beat(4)11.88%
Revenue beat(8)8
Avg Revenue beat(8)5.58%
Revenue beat(12)12
Avg Revenue beat(12)6.21%
Revenue beat(16)16
Avg Revenue beat(16)7%
PT rev (1m)3.49%
PT rev (3m)19.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)821.98%
EPS NY rev (1m)0%
EPS NY rev (3m)174.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 84.53 | ||
| P/S | 8.29 | ||
| P/FCF | 62.41 | ||
| P/OCF | 53.3 | ||
| P/B | 3 | ||
| P/tB | 11.55 | ||
| EV/EBITDA | 101.11 |
EPS(TTM)-0.15
EYN/A
EPS(NY)0.54
Fwd EY1.18%
FCF(TTM)0.73
FCFY1.6%
OCF(TTM)0.85
OCFY1.88%
SpS5.49
BVpS15.17
TBVpS3.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.73% | ||
| ROE | -0.79% | ||
| ROCE | 0.76% | ||
| ROIC | 0.6% | ||
| ROICexc | 0.77% | ||
| ROICexgc | 12.07% | ||
| OM | 2.14% | ||
| PM (TTM) | N/A | ||
| GM | 68.45% | ||
| FCFM | 13.28% |
ROA(3y)-5.4%
ROA(5y)-5.68%
ROE(3y)-5.81%
ROE(5y)-6.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.04%
GM growth 5Y1.43%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 40.97% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 202.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.08 | ||
| Quick Ratio | 4.79 | ||
| Altman-Z | 21.81 |
F-Score7
WACC10.75%
ROIC/WACC0.06
Cap/Depr(3y)32.36%
Cap/Depr(5y)39.97%
Cap/Sales(3y)2.7%
Cap/Sales(5y)2.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%146.34%
EPS Next Y133.81%
EPS Next 2Y58.82%
EPS Next 3Y41.29%
EPS Next 5Y29.09%
Revenue 1Y (TTM)23.95%
Revenue growth 3Y45.38%
Revenue growth 5Y31.45%
Sales Q2Q%28.58%
Revenue Next Year24.95%
Revenue Next 2Y17.23%
Revenue Next 3Y14.98%
Revenue Next 5Y11.87%
EBIT growth 1Y146.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year247.43%
EBIT Next 3Y62.73%
EBIT Next 5Y39.45%
FCF growth 1Y4512.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y959.68%
OCF growth 3YN/A
OCF growth 5YN/A